vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Hillman Solutions Corp. (HLMN). Click either name above to swap in a different company.
Hillman Solutions Corp. is the larger business by last-quarter revenue ($370.1M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -1.3%, a 12.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 3.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-34.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -1.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Hillman Solutions is an American hardware manufacturing, distribution and consumer fabrication services company.
ANIP vs HLMN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $370.1M |
| Net Profit | $27.5M | $-4.7M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 1.9% |
| Net Margin | 11.1% | -1.3% |
| Revenue YoY | 29.6% | 3.0% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $370.1M | ||
| Q4 25 | $247.1M | $365.1M | ||
| Q3 25 | $227.8M | $424.9M | ||
| Q2 25 | $211.4M | $402.8M | ||
| Q1 25 | $197.1M | $359.3M | ||
| Q4 24 | $190.6M | $349.6M | ||
| Q3 24 | $148.3M | $393.3M | ||
| Q2 24 | $138.0M | $379.4M |
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $27.5M | $1.6M | ||
| Q3 25 | $26.6M | $23.2M | ||
| Q2 25 | $8.5M | $15.8M | ||
| Q1 25 | $15.7M | $-317.0K | ||
| Q4 24 | $-10.3M | $-1.2M | ||
| Q3 24 | $-24.2M | $7.4M | ||
| Q2 24 | $-2.3M | $12.5M |
| Q1 26 | — | 1.9% | ||
| Q4 25 | 14.1% | 4.6% | ||
| Q3 25 | 15.9% | 10.8% | ||
| Q2 25 | 6.6% | 9.0% | ||
| Q1 25 | 13.3% | 4.2% | ||
| Q4 24 | -2.3% | 4.0% | ||
| Q3 24 | -13.8% | 6.8% | ||
| Q2 24 | 3.7% | 8.3% |
| Q1 26 | — | -1.3% | ||
| Q4 25 | 11.1% | 0.4% | ||
| Q3 25 | 11.7% | 5.5% | ||
| Q2 25 | 4.0% | 3.9% | ||
| Q1 25 | 8.0% | -0.1% | ||
| Q4 24 | -5.4% | -0.3% | ||
| Q3 24 | -16.3% | 1.9% | ||
| Q2 24 | -1.7% | 3.3% |
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $1.14 | $0.00 | ||
| Q3 25 | $1.13 | $0.12 | ||
| Q2 25 | $0.36 | $0.08 | ||
| Q1 25 | $0.69 | $0.00 | ||
| Q4 24 | $-0.45 | $-0.00 | ||
| Q3 24 | $-1.27 | $0.04 | ||
| Q2 24 | $-0.14 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $27.7M |
| Total DebtLower is stronger | — | $714.1M |
| Stockholders' EquityBook value | $540.7M | $1.2B |
| Total Assets | $1.4B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.59× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $27.7M | ||
| Q4 25 | $285.6M | $27.3M | ||
| Q3 25 | $262.6M | $37.7M | ||
| Q2 25 | $217.8M | $34.2M | ||
| Q1 25 | $149.8M | $36.3M | ||
| Q4 24 | $144.9M | $44.5M | ||
| Q3 24 | $145.0M | $59.8M | ||
| Q2 24 | $240.1M | $54.0M |
| Q1 26 | — | $714.1M | ||
| Q4 25 | — | $668.3M | ||
| Q3 25 | — | $683.2M | ||
| Q2 25 | — | $683.1M | ||
| Q1 25 | — | $713.5M | ||
| Q4 24 | — | $691.7M | ||
| Q3 24 | — | $730.7M | ||
| Q2 24 | — | $732.1M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $540.7M | $1.2B | ||
| Q3 25 | $505.8M | $1.2B | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $1.2B | ||
| Q4 24 | $403.7M | $1.2B | ||
| Q3 24 | $405.9M | $1.2B | ||
| Q2 24 | $455.8M | $1.2B |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.4B | ||
| Q1 25 | $1.3B | $2.3B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $920.8M | $2.4B |
| Q1 26 | — | 0.59× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.62× | ||
| Q2 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | $-34.3M |
| FCF MarginFCF / Revenue | 11.8% | -9.3% |
| Capex IntensityCapex / Revenue | 0.5% | 4.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $30.9M | ||
| Q3 25 | $44.1M | $26.2M | ||
| Q2 25 | $75.8M | $48.7M | ||
| Q1 25 | $35.0M | $-655.0K | ||
| Q4 24 | $15.9M | $43.1M | ||
| Q3 24 | $12.5M | $63.7M | ||
| Q2 24 | $17.4M | $64.8M |
| Q1 26 | — | $-34.3M | ||
| Q4 25 | $29.1M | $16.1M | ||
| Q3 25 | $38.0M | $9.1M | ||
| Q2 25 | $71.8M | $31.2M | ||
| Q1 25 | $32.5M | $-21.3M | ||
| Q4 24 | $13.5M | $22.1M | ||
| Q3 24 | $7.7M | $39.6M | ||
| Q2 24 | $13.0M | $42.5M |
| Q1 26 | — | -9.3% | ||
| Q4 25 | 11.8% | 4.4% | ||
| Q3 25 | 16.7% | 2.1% | ||
| Q2 25 | 34.0% | 7.7% | ||
| Q1 25 | 16.5% | -5.9% | ||
| Q4 24 | 7.1% | 6.3% | ||
| Q3 24 | 5.2% | 10.1% | ||
| Q2 24 | 9.4% | 11.2% |
| Q1 26 | — | 4.0% | ||
| Q4 25 | 0.5% | 4.0% | ||
| Q3 25 | 2.7% | 4.0% | ||
| Q2 25 | 1.9% | 4.3% | ||
| Q1 25 | 1.3% | 5.7% | ||
| Q4 24 | 1.3% | 6.0% | ||
| Q3 24 | 3.2% | 6.1% | ||
| Q2 24 | 3.2% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 19.33× | ||
| Q3 25 | 1.66× | 1.13× | ||
| Q2 25 | 8.87× | 3.08× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.57× | ||
| Q2 24 | — | 5.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
HLMN
Segment breakdown not available.
